DRTS

ANALYST NOTE: DRTS (Alpha Tau Medical Ltd.) Date: 2026-06-13 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

Conservative Entry: $9.88 Current Price: $9.78 Extension: -1.0% vs. conservative entry Breakout Level: $9.88 (Conservative Entry)

Structural Assessment:

2. Thesis Layer

Primary Secular Thesis: Biotech & GLP-1 → Oncology (Tier Direct, High Confidence) Exposure Analysis: Alpha Tau Medical Ltd. is a direct beneficiary of the secular shift toward targeted oncology therapies, specifically those leveraging immunotherapy mechanisms. The company's Alpha DaRT® technology is positioned to activate systemic anti-tumor immune reactivity through the in-situ destruction of solid cancers.

The "Biotech & GLP-1" classification in the thesis membership reflects the broader market's focus on high-growth therapeutic modalities. While DRTS does not produce GLP-1 agonists, its exposure to the "Oncology" sub-theme within this bucket is direct. The company's role is that of a technology platform developer targeting metastatic disease, a high-unmet-need area that aligns with the sector's growth trajectory. There are no additional secular themes listed in the current evidence base; the conviction rests entirely on the direct exposure to the oncology immunotherapy wave.

3. Business Overview

Business Model & Industry: Alpha Tau Medical Ltd. operates in the medical device and biotechnology sector, focusing on the development and commercialization of Alpha DaRT® (Dynamic Radionuclide Therapy). The company's core value proposition is the use of sealed radioactive sources to deliver localized radiation therapy that simultaneously destroys tumor cells and stimulates a systemic immune response.

Key Operational Details (as of 2026-06-13):

• Technology Origin: The Alpha DaRT® technology was invented in 2003 by co-founders Professor Yona Keisari and Professor Itzhak Kelson.
• Clinical Focus: The company's research, led by Prof. Keisari, targets the activation of systemic anti-tumor immune reactivity and the improved eradication of metastases through in-situ cancer destruction.
• Leadership: Dr. Robert Den has served as Chief Medical Officer since 2019, bringing specialized expertise in radiation oncology and research across a broad variety of malignancies.
• Financial Structure: As of the March 9, 2026 filing, the company remains an "Emerging Growth Company" (EGC). Management expects this status to persist until the earlier of: (i) reaching $1.235 billion in annual gross revenues, (ii) issuing over $1 billion in nonconvertible debt, (iii) becoming a large accelerated filer, or (iv) December 31, 2027.
• Compensation & Burn: Management guidance recorded in the March 2026 filing indicates an expectation for aggregate base compensation for executive officers and directors of approximately $2.8 million for the fiscal year 2026. This follows a 2025 actuals figure of approximately $3.96 million in aggregate cash compensation and benefits in kind.

4. Archetype and Conviction Stack

Archetype: Growth Leader (Pre-Revenue/Early Commercial) / Deep Value Recovery (Potential) Valuation & Conviction Context: Alpha Tau fits the archetype of a high-risk, high-reward Growth Leader in the biotech space, characterized by a proprietary technology platform with significant commercial potential but a reliance on future clinical milestones and revenue generation.

• Thesis Strength: High. The direct link to the oncology immunotherapy trend provides a strong secular tailwind. The technology addresses a specific, high-value clinical need (metastatic solid tumors).
• Evidence Quality: Moderate. The evidence base relies heavily on SEC filings regarding corporate structure, leadership, and compensation. There is a lack of specific clinical trial data or revenue figures in the provided evidence block for 2026, which is typical for an EGC but limits the ability to assess commercial traction.
• Structural Quality: The ATR metrics present a mixed signal. The "Very High" ATR at breakout (7.8%) and "Extreme" current ATR (8.4%) indicate significant volatility. In the StoryStocks canon, extreme ATR (>8%) is historically associated with a higher rate of severe losers, suggesting that while the setup is forming, the price action is unstable.
• Rerating Potential: High, contingent on clinical data releases or commercial partnerships, which are not detailed in the current evidence.

5. Invalidation, Strengthening, and Gaps

Invalidation Triggers:

• A failure to maintain the "Emerging Growth Company" status or a significant dilution event that alters the capital structure beyond the $1 billion debt threshold (though unlikely given the current trajectory).

Strengthening Factors:

• A confirmed close above $9.88 would trigger the "Confirmed" state, validating the breakout.
• Positive clinical trial updates or regulatory approvals (not currently in evidence) would significantly strengthen the thesis.
• Evidence of revenue growth or a strategic partnership would validate the business model.

Evidence Gaps:

• Clinical Data: There is no specific evidence in the provided block regarding the status of ongoing clinical trials, patient enrollment numbers, or specific efficacy data for 2026.
• Revenue/Traction: No revenue figures or commercial sales data are provided for 2026, making it impossible to assess the commercialization progress of the Alpha DaRT® technology.
• Cash Runway: While executive compensation is detailed, there is no explicit evidence regarding the company's total cash balance, burn rate, or runway in the provided text.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key risks: Extreme ATR volatility (8.4%) indicates high risk of severe loss; Lack of clinical or revenue data in current evidence base; Company remains an Emerging Growth Company with no revenue threshold met. Sizing hint: Position size must be minimal due to extreme volatility and unconfirmed breakout; treat as a lottery ticket on the setup completion. Expected path: Management expects to remain an EGC through 2027; price action likely to remain volatile until a confirmed breakout above $9.88 or a clinical catalyst emerges. Expected horizon: 3 to 6 months for a potential breakout or structural invalidation. Failure mode to watch: A daily close below $7.17, which would invalidate the coil structure and signal a sell.